Advertisement
UK markets open in 3 hours 16 minutes

  • NIKKEI 225

    37,818.11
    -641.97 (-1.67%)
     

  • HANG SENG

    17,325.71
    +124.44 (+0.72%)
     

  • CRUDE OIL

    82.80
    -0.01 (-0.01%)
     

  • GOLD FUTURES

    2,320.50
    -17.90 (-0.77%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,687.51
    -1,826.31 (-3.41%)
     

  • CMC Crypto 200

    1,389.23
    -34.87 (-2.45%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

COVID-19 Impact on Novavax Inc

Research and Markets
·1-min read

Dublin, Feb. 01, 2021 (GLOBE NEWSWIRE) -- The "Coronavirus Disease 2019 (COVID-19) Impact on Novavax Inc." company profile has been added to ResearchAndMarkets.com's offering.

Novavax is a late-stage clinical biotechnology company with a recombinant subunit innovative vaccine platform and an adjuvant platform to develop prophylactic vaccines against infectious diseases.

Scope

  • This report gives an important expert analysis on how COVID-19 will affect Novavax. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Reasons to Buy

  • An overview of how Novavax Inc. will be affected by the COVID-19 pandemic.

ADVERTISEMENT

Key Topics Covered:

1 Executive Summary

2 Company Overview

3 Regional Analysis

4 Reaction to COVID-19

5 Key Findings

6 Appendix

For more information about this company profile visit https://www.researchandmarkets.com/r/isdfgd

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900